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ABSTRACT: Eukaryotic translation initiation factor 4G (eIF4G) plays a crucial role in
translation initiation, serving as a scaﬀolding protein binding several other initiation factors,
other proteins, and RNA. Binding of eIF4G to the ATP-dependent RNA helicase eukaryotic
translation initiation factor 4A (eIF4A) enhances the activity of eIF4A in solution and in
crowded environments. Previously, this activity enhancement was solely attributed to eIF4G,
conferring a closed, active conformation upon eIF4A. Here we show that eIF4G contains a low-
aﬃnity binding site at the entrance to the ATP-binding cleft on eIF4A, suggesting that regulation
of the local ATP concentration may be an additional reason for the enhancement in activity.
The control of translation (mRNA-encoded proteinsynthesis) is crucial for cell proliferation and diﬀer-
entiation. More than 10 eukaryotic translation initiation factors
are known to be involved in the assembly of the 80S ribosome/
RNA complex, allowing placement of the initiator Met-tRNA at
the correct start codon of the mRNA.1 The dominant
mechanism used by cellular mRNAs, named cap-dependent
translation, requires the recognition of the 5′ m7G cap
structure of the mRNA by the cap binding complex eIF4F.
The eIF4F complex is composed of cap-binding subunit eIF4E,
RNA helicase eukaryotic translation initiation factor 4A
(eIF4A), and scaﬀolding protein eukaryotic translation
initiation factor 4G (eIF4G).2−4 Eukaryotic translation factor
4A (eIF4A) is the prototypic member of the DEAD-box family
of RNA helicases,5 a subfamily of superfamily 2 (SF2) of RNA
helicases.6 ATP-dependent RNA helicase eIF4A unwinds
secondary structure in the 5′ untranslated region (UTR) of
mRNAs to facilitate 40S ribosome binding and scanning for the
start codon. eIF4A by itself is a poor ATPase and helicase (kcat
= 3 min−1).7 However, these activities are stimulated when
eIF4A is part of a multiprotein complex including eIF4G,
eIF4E, eIF4B, and/or eIF4H.8−12
eIF4G plays a crucial role in translation initiation, serving as a
scaﬀolding protein that binds several initiation factors (the cap-
binding protein eIF4E, the RNA helicase eIF4A, and eIF3) and
other proteins [poly(A)-binding protein, eIF4E kinase, and
Mnk]. Human eIF4G contains three HEAT repeat domains in
the C-terminal two-thirds of its sequence. The ﬁrst two,
HEAT1 and HEAT2, contain binding sites for the ATP-
dependent RNA helicase eIF4A. It has been shown that the
interaction with HEAT1 enhances the activity of eIF4A by 4-
fold in solution.13
In solution, eIF4A exists in a ﬂexible, open conformation.
eIf4G-HEAT1 forms a soft clamp conferring a closed
conformation upon eIF4A. The enhancement in activity was
generally attributed to this change from the open to the closed,
active conformation.14 Assuming the only reason for the
enhancement in activity stems from the binding of eIF4G and
the accompanying change to the closed conformation, no
additional enhancement would be expected once eIf4A is in the
closed conformation. We have recently shown that macro-
molecular crowding shifts the equilibrium toward the closed,
active conformation of eIF4A. However, additional enhance-
ment of eIF4A activity is observed in the presence of eIf4G-
HEAT1.15 This additional enhancement suggests that the
conformational change is not the only reason for the increase in
activity.
The crystal structure of eIF4GII-HEAT1 was determined
using X-ray crystallography; however, the structure of a 40-
residue loop was not resolved.16 The structure of free yeast
eIF4A was successfully determined,17 but no structure for free
full length human eIF4A is available. The two recA-like
domains are very similar among the DEAD-box helicases;
however, the interdomain angle varies greatly. A structure of
the closed conformation of human eIF4A in complex with
PCDC4 is available18 and is very similar to the structure of
yeast eIF4A in complex with yeast eIF4GII-HEAT1.19 We
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recently reported the low-resolution structures of human eIF4A
and its complex with eIF4G1-HEAT1 in buﬀer and a crowded
environment showing a signiﬁcant structural diﬀerence.15
Here we report the discovery of a low-aﬃnity ATP binding
site on eIF4GI-HEAT1 that is located just opposite the ATP-
binding cleft of eif4A. The sequence of this binding site does
not resemble any known ATP binding sites, which have much
higher binding aﬃnities. This low-aﬃnity ATP binding site
might play a role in the enhancement of eIF4A activity by
regulating local ATP concentrations.
eIF4G-HEAT1 was expressed and puriﬁed as described
previously.20 15N- and D-labeled eIF4G-HEAT1 was expressed
in minimal medium. ATP was purchased from Roche Molecular
Biochemicals. Poly(U) was purchased from Dharmacon. For
nuclear magnetic resonance (NMR) samples, the 15N- and D-
labeled protein was concentrated using Millipore (Bedford,
MA) Centricons to a ﬁnal concentration of 0.4 mM in a buﬀer
consisting of 10 mM sodium phosphate (pH 6.5), 150 mM
NaCl, 20 mM MgCl2, 2 mM DTT, and 0.5 mM EDTA with
increasing concentrations of ATP at ATP:eIF4G-HEAT1 ratios
of 0:1, 1:1, 15:1, and 25:1, with increasing poly(U)
concentrations at poly(U):eIF4G-HEAT1 ratios of 0:1, 0.5:1,
1:1, and 3:1, or with a poly(U):ATP:eif4G-HEAT1 ratio of
15:1:1. 15N TROSY-HSQC spectra were recorded at 298 K on
a Bruker Avance DRX 600 MHz spectrometer equipped with a
TCI cryoprobe with a Z gradient and processed using
NMRPipe21 and NMRViewJ.22 The dimensions were set to
2048 (1H) and 400 (15N) points, respectively, corresponding to
spectral widths of 12 (1H) and 32 (15N) ppm, respectively.
eIF4G-HEAT1 backbone assignment was performed as
described previously.20 Unlabeled protein samples for X-ray
absorption near edge spectroscopy (XANES) were concen-
trated to ﬁnal concentrations of 0.3−0.7 mM. Each sample
contained 300 μM MnCl2 and ATP in a buﬀer consisting of 20
mM MES (pH 6.5), 150 mM NaCl, 2 mM DTT, 10% glycerol,
and increasing concentrations of eIF4G-HEAT1 (0, 0.3, 0.5,
and 0.7 mM). The sample components were mixed at ∼0 °C
and immediately frozen in copper sample holders (10 mm × 5
mm × 0.5 mm) covered with Mylar using liquid nitrogen.
XANES data were collected at the National Synchroton Light
Source at beamline X3B of Brookhaven National Laboratory.
Spectra were recorded as described previously.23,24 Examination
of the samples for visual signs of photoreduction after each scan
and sodium dodecyl sulfate−polyacrylamide gel electrophoresis
gels after exposure revealed no signs of burn marks, radiation
damage, or protein degradation. Data were processed as
described previously using Athena X-ray absorption spectros-
copy (XAS) data analysis software.25
We recorded 15N−1H TROSY-HSQC spectra of [15N,D]-
eIf4G-HEAT1 with increasing concentrations of ATP with
ATP:eIF4G-HEAT ratios from 0:1 to 25:1 to determine
whether ATP binds to eIF4G-HEAT1. The overlay of these
spectra for selected residues is shown in Figure 1a. The entire
spectrum is shown in Figure S1 of the Supporting Information.
Several peaks shifted upon addition of ATP, indicating a
binding event. Plotting the changes in chemical shifts versus
residue number (Figure S4 of the Supporting Information) and
mapping these changes on the structural model of eIF4G-
HEAT1 (Figure S5 of the Supporting Information) reveal a
contiguous binding site in the N-terminal region, including
residues L926, K927, H929, D930, and E931. To conﬁrm that
Mg-ATP is the binding partner and not just Mg2+, we measured
TROSY-HSQC spectra of eIF4G-HEAT1 alone, with Mg2+
only, with ATP alone, and with Mg2+ and ATP (Figure 1b).
Residues L926 and H929 show chemical shift changes after
addition of Mg2+ alone and ATP alone and an additional shift
for the combination of Mg2+ and ATP. These chages in
chemical shifts would suggest that both Mg2+ and ATP can bind
alone to eIF4G-HEAT but that binding of Mg-ATP leads to a
change in chemical shift greater than that of either alone.
Residue 931 does not show a chemical shift change after
addition of Mg2+ alone, however, but shows the same change
for either ATP alone or Mg-ATP. This would suggest that
binding to E931 is not mediated by Mg2+ as was observed for
the other two residues. Figure S2 of the Supporting
Information shows the plot of chemical shift change versus
ATP concentration for residues showing the largest chemical
shift changes as well as other residues with little or no change
for comparison. This graph illustrates clearly that the binding
site is a low-aﬃnity binding site as the curve does not show
saturation even at high ATP concentrations.
As the observed chemical shift changes are relatively small,
we used X-ray absorption near edge spectroscopy (XANES) as
an independent method to conﬁrm binding of ATP to eIF4G-
HEAT1. XAS utilizes the photoelectric eﬀect in which an X-ray
is absorbed and a core level electron is promoted out of the
atom. If the energy of the incident X-ray is equal to that of the
binding energy of a core level electron, the absorption energy
increases signiﬁcantly. This increase in absorption is called the
absorption edge. The energy at which the edge occurs varies on
the basis of several characteristics such as the oxidation state of
the atom, coordination, and the distances as well as
coordination number and species of the atoms immediately
surrounding the selected element. ATP binding is mediated by
Mg2+. However, probing Mg using XAS is technically diﬃcult,
and we therefore substituted Mn2+ for Mg2+. Mn2+ is used
extensively to substitute for the often spectroscopically silent
Mg2+ because of the similarity of their properties,26 including
similar constants for binding to ATP.27 In contrast to the NMR
titration experiment in which ATP is the titrant, for X-ray
absorption the concentration of Mn-ATP is constant. The
absorption energy of Mn2+ as the cofactor of ATP was
measured at increasing concentrations of eIF4G-HEAT1
Figure 1. Binding of ATP to eIF4G-HEAT1 as determined by NMR.
(a) Titration of ATP to 4GH1 monitored by 1H−15N TROSY-HSQC
spectra. The eIF4G-HEAT1:ATP ratio varied from 1:0 to 1:25 as
indicated by the color coding in the legend and shown for excerpts for
selected residues showing large chemical shift changes upon addition
of ATP. The full spectrum is shown in Figure S1 of the Supporting
Information. (b) Overlay of 15N TROSY-HSQC spectra of eIF4G-
HEAT (black), eIF4G-HEAT with Mg2+ (blue), eIF4G-HEAT1 with
ATP (orange), and eIF4G-HEAT1 with Mg2+ and ATP (red).
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ranging from 0 to 0.7 mM. The energy proﬁles of these samples
are shown in Figure 2a. Figure 2b shows the plot of the
absorption edge versus eIF4G-HEAT1 concentration. The
energy increases with increasing concentration, and the curve
shows the characteristics of a typical binding curve. Binding is
not saturated at 0.7 mM eIF4G-HEAT1; however, eIF4G-
HEAT1 is not stable at higher concentrations. Together with
the relatively small chemical shift changes and the inability to
determine the binding constant with surface plasmon resonance
(data not shown), this suggests that the binding site has a low
aﬃnity for ATP.
eIF4G-HEAT is known to bind to RNA.28,29 Determination
of the binding site of RNA [poly(U)] reveals that the binding
sites for poly(U) and ATP do not overlap (see Figures S1−S3
of the Supporting Information). Although binding sites are
distinct, binding of ATP to the eif4G-HEAT1 complex induces
slight chemical shift changes for the residues involved in RNA
binding. Chemical shifts for residues involved in ATP binding
in these samples are slighlty diﬀerent as well compared to those
of the eIF4G-HEAT/ATP complex (see Figure S1 of the
Supporting Information), which might suggest that RNA and
ATP are able to bind to eIF4G-HEAT1 at the same time, but
additional experiments would be needed to conﬁrm this claim.
eIF4A is an ATP-dependent RNA helicase binding to eIF4G-
HEAT1. The activity of eIF4A is enhanced by binding of
eIF4G-HEAT1. The accepted mechanism for this enhancement
was that in which eIF4G confers the closed, active
conformation on eIF4A upon binding. We recently showed
that the closed conformation of eIF4A is the preferred
conformation in a crowded environment mimicking the cellular
environment.15 The ATPase activity of eIF4A is enhanced in a
crowded environment without binding to eIF4G, which can be
attributed to the conformational change. Binding of eIF4G-
HEAT1 to eIF4A leads to an additional increase in activity.
Comparison of the structure of the complex in solution and
in the crowded environment showed a compaction of the latter.
Mapping the ATP binding site on eIF4GI-HEAT1 in a model
of the eIF4GI-HEAT1/eIF4A complex reveals that the binding
site is located right at the entrance to the binding cleft, opposite
the ATP binding site on eIF4A (Figure 3).
The rate-limiting step in solution of the catalytic cycle of
eIF4A was shown to be the release of phosphate after ATP
hydrolysis.31,32 This release is accelerated through interaction
with eIF4G.31 We showed previously that rate of ATP
hydrolysis is increased in the presence of a crowding agent
even without binding of eIF4G, which can be attributed to the
fact that the crowded environment confers the closed, active
conformation upon eIf4A.15 However, an additional enhance-
ment by binding of eIF4G to eIF4A is observed in a crowded
environment, suggesting an additional reason for the activity
enhancement. The additional enhancement of the activity of
eIF4A by eIF4G could be explained by the presence of the ATP
binding site on eIF4G-HEAT1. Binding of ATP in the
proximity of the active site would not only increase the
eﬀective concentration of ATP but also reduce the entropy of
the substrate by removing solvent molecules bound to ATP.
However, additional experiments for studying this hypothesis
would be needed.
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